Clinical trial
suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by…
NCT04680949 · Hellenic Institute for the Study of Sepsis, Other · Completed
Key facts
| NCT number | NCT04680949 |
|---|---|
| Title | suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19 |
| Official title | suPAR-Guided Anakinra Treatment for Validation of the Risk and Early Management of Severe Respiratory Failure by COVID-19: The SAVE-MORE Double-blind, Randomized, Phase III Confirmatory Trial |
| Acronym | SAVE-MORE |
| Lead sponsor | Hellenic Institute for the Study of Sepsis, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Covid19 |
| Intervention type | Drug |
| Interventions | Anakinra, Placebo |
| Enrollment | 606 |
| Start date | Dec 23, 2020 |
| Primary completion | Mar 31, 2021 |
| Completion | Feb 6, 2022 |
| First posted | Dec 23, 2020 |
| Last update posted | Sep 6, 2022 |
| Countries | Greece, Italy |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: